Healing/Gut

BPC-157

Synthetic pentadecapeptide derived from a protective protein found in gastric juice, studied for tissue repair and gut health.

For educational and research use only. Not intended for human or animal consumption. Always consult a qualified healthcare professional before starting any protocol.

Overview & mechanism

BPC-157 (Body Protection Compound-157) is a 15-amino-acid fragment derived from a protein isolated from human gastric juice. Preclinical research has explored its role in accelerating repair of tendons, ligaments, muscle, and the gastrointestinal lining. Proposed mechanisms include upregulation of VEGF-mediated angiogenesis, modulation of the nitric oxide system, and interaction with growth-hormone receptor signaling in injured tissue.

Research dose & half-life

Half-life:: ~4 hours (systemic); local tissue effects appear longer
Research dose:: Common research protocols: 250–500 mcg 1–2x daily, subcutaneous near the area of interest, for 2–6 weeks. Alternative protocol: 300–500 mcg 3x weekly (e.g., Mon/Wed/Fri) for longer-term maintenance or mild injury research.
Protocol notes:: Schedule: subcutaneous, ideally at the same time each day; for local injury research, inject near the affected area. Start/stop: run daily protocols 2–6 weeks, then reassess; 3x-weekly maintenance can continue for several weeks if tolerated. Cautions: avoid injecting through infected or irritated skin; discontinue if redness, warmth, or persistent pain develops.

Safety & side effects

Commonly reported in research: mild injection-site redness or bruising, transient dizziness, temporary appetite changes, and mild GI upset. Theoretical concerns from limited data: influence on angiogenesis (use caution with active tumors), possible interaction with blood-pressure regulation. Not studied in pregnancy, pediatrics, or long-term human use. Stop and seek medical guidance for chest pain, severe headache, or any allergic reaction.

Deep dive

How BPC-157 is thought to work

BPC-157 appears to upregulate VEGF-A and eNOS in injured tissue, which accelerates the formation of new capillaries and improves local blood flow to tendons, ligaments, and gut lining. It also interacts with growth-hormone receptor expression in fibroblasts, which may explain why several rodent tendon-transection studies show faster collagen alignment and higher tensile strength versus saline controls.

Subcutaneous vs. local injection

Rodent studies show benefit from both intraperitoneal and subcutaneous administration far from the injury site, suggesting a systemic mechanism. In practice, most research protocols use subcutaneous dosing near the area of interest — for example, a tender Achilles or elbow — because it is simple and delivers a higher local concentration without needing intra-articular access.

Stacking notes

BPC-157 is frequently paired with TB-500 (see the Wolverine Blend page) for broader soft-tissue coverage. It is also commonly cycled alongside GHK-Cu when the research focus is skin or wound remodeling. There is no known negative interaction with metabolic research peptides, but starting one variable at a time is standard practice so effects can be attributed cleanly.

Frequently asked questions

How long does BPC-157 take to work in research protocols?

Most published animal work and anecdotal human research reports directional changes within 1–2 weeks, with more meaningful tissue remodeling observed across a full 4–6 week course. Chronic injuries typically need longer courses than acute ones.

Is BPC-157 stable at room temperature once reconstituted?

Reconstituted BPC-157 is best kept refrigerated and used within 3–4 weeks. Short excursions to room temperature during dosing are acceptable; prolonged heat exposure or freeze/thaw cycles are not.

Does BPC-157 need to be cycled?

Most research designs use 2–6 week on-cycles followed by a break of equal or longer duration. There is no evidence of receptor downregulation, but breaks are still standard to reassess baseline before continuing.

Can BPC-157 be combined with TB-500?

Yes — the two are commonly co-administered in research (see the Wolverine Blend). They target complementary pathways: BPC-157 acts more locally on angiogenesis and gut lining, TB-500 acts more systemically on actin dynamics and cell migration.

Back to education library